European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026
Cardiac Resynchronization Therapy for Failing Single Ventricle Physiology.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tominaga Yuji, Sakaguchi Heima, Takeshita Masashi, Watanabe Takuji, Shibagaki Keisuke, Nakamizo Masaya, Kurosaki Kenichi, Iwai Shigemitsu
Аннотация
OBJECTIVES: We aimed to evaluate the mid-term outcomes of cardiac resynchronization therapy (CRT) in patients with single ventricle (SV), heart failure, and ventricular dyssynchrony, which leads to heart failure and poor outcomes.
METHODS: We retrospectively reviewed patients with SV who underwent CRT at our institution between 2010 and 2024. Dyssynchrony was defined as QRS duration ≥130 ms and qualitative mechanical dyssynchrony between the main and rudimentary ventricles assessed by echocardiography and cine-angiography. Cardiac resynchronization therapy indications were based on acute haemodynamic studies (shortened QRS duration and increased peak dP/dt). The patients were divided into Groups G (CRT after bidirectional Glenn) and F (after Fontan completion). Haemodynamic parameters, NYHA class, brain natriuretic peptide, survival, Fontan completion rate, and hepatic function were analysed.
RESULTS: Group G included 9 and Group F included 11 patients. One year after CRT, the systemic ventricular ejection fraction improved in Groups G (30%-40%, P = .006) and F (30%-53%, P = .001), with corresponding increases in cardiac index and NYHA class. The median follow-up was 6.7 years (Group G) and 7.6 years (Group F). The 5-year survival rates were 89% and 82%, respectively. The Fontan completion rate was 76% at 5 years in Group G. In Group F, brain natriuretic peptide levels improved, hepatic function remained stable, and no protein-losing enteropathy was reported.
CONCLUSIONS: Cardiac resynchronization therapy improved systemic ventricular function and heart failure symptoms. Cardiac resynchronization therapy might be a viable therapeutic option for patients with SV, ventricular dyssynchrony, and heart failure.
METHODS: We retrospectively reviewed patients with SV who underwent CRT at our institution between 2010 and 2024. Dyssynchrony was defined as QRS duration ≥130 ms and qualitative mechanical dyssynchrony between the main and rudimentary ventricles assessed by echocardiography and cine-angiography. Cardiac resynchronization therapy indications were based on acute haemodynamic studies (shortened QRS duration and increased peak dP/dt). The patients were divided into Groups G (CRT after bidirectional Glenn) and F (after Fontan completion). Haemodynamic parameters, NYHA class, brain natriuretic peptide, survival, Fontan completion rate, and hepatic function were analysed.
RESULTS: Group G included 9 and Group F included 11 patients. One year after CRT, the systemic ventricular ejection fraction improved in Groups G (30%-40%, P = .006) and F (30%-53%, P = .001), with corresponding increases in cardiac index and NYHA class. The median follow-up was 6.7 years (Group G) and 7.6 years (Group F). The 5-year survival rates were 89% and 82%, respectively. The Fontan completion rate was 76% at 5 years in Group G. In Group F, brain natriuretic peptide levels improved, hepatic function remained stable, and no protein-losing enteropathy was reported.
CONCLUSIONS: Cardiac resynchronization therapy improved systemic ventricular function and heart failure symptoms. Cardiac resynchronization therapy might be a viable therapeutic option for patients with SV, ventricular dyssynchrony, and heart failure.